Kura Oncology (KURA) Cut to “Hold” at Zacks Investment Research

Share on StockTwits

Kura Oncology (NASDAQ:KURA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

A number of other brokerages have also recently commented on KURA. BidaskClub cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Oppenheimer reiterated a “buy” rating on shares of Kura Oncology in a report on Tuesday, March 19th. ValuEngine cut Kura Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, February 13th. Finally, HC Wainwright set a $31.00 target price on Kura Oncology and gave the company a “buy” rating in a report on Wednesday. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Kura Oncology has an average rating of “Buy” and an average price target of $28.20.

NASDAQ KURA opened at $16.96 on Thursday. Kura Oncology has a 1-year low of $10.20 and a 1-year high of $22.00. The company has a market capitalization of $647.62 million, a P/E ratio of -9.86 and a beta of 2.79. The company has a quick ratio of 13.31, a current ratio of 13.31 and a debt-to-equity ratio of 0.05.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.08. On average, equities research analysts expect that Kura Oncology will post -1.91 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the business. CWM LLC acquired a new stake in Kura Oncology during the 1st quarter valued at $25,000. Legacy Advisors LLC acquired a new stake in Kura Oncology during the 1st quarter valued at $65,000. Great West Life Assurance Co. Can acquired a new stake in Kura Oncology during the 4th quarter valued at $62,000. Legal & General Group Plc grew its holdings in Kura Oncology by 21.7% during the 4th quarter. Legal & General Group Plc now owns 5,175 shares of the company’s stock valued at $73,000 after buying an additional 923 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in Kura Oncology by 293,950.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 5,881 shares of the company’s stock valued at $98,000 after buying an additional 5,879 shares during the last quarter. Hedge funds and other institutional investors own 84.99% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

See Also: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.